Evidence map›Paper›PMID 40918813›Full record

ArticleCureus2025

Recurrent Grade I Parafalcine Meningioma: Management Challenges and Genomic Insights.

Jenna R Rocchetti, Nilanjan Haldar, Debanjan Haldar, David W Andrews, Maria Werner-Wasik

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jenna R RocchettiRadiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA.
Nilanjan HaldarRadiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA.
Debanjan HaldarNeurosurgery, Thomas Jefferson University Hospital, Philadelphia, USA.
David W AndrewsNeurosurgery, Thomas Jefferson University Hospital, Philadelphia, USA.
Maria Werner-WasikRadiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While World Health Organization (WHO) grade I meningiomas are typically slow growing and associated with favorable prognoses, a subset may exhibit unexpectedly aggressive behavior and resistance to conventional treatment approaches. Recurrent grade I meningiomas, in particular, are associated with a poorer prognosis despite their benign histological classification, underscoring the need for advanced genomic and radiomic analyses to refine diagnostic accuracy. We present a case of a 52-year-old female with a grade I parafalcine meningioma initially deemed nonaggressive, but ultimately recurred multiple times over several years despite undergoing repeated craniotomies and several courses of radiosurgery. Notable tumor characteristics included its supratentorial location, high Ki-67 proliferative index, and NF-2 genetic alteration, which are all factors associated with decreased progression-free survival in grade I meningioma patients. The patient remains clinically stable eight months post salvage stereotactic radiation therapy (SRT). This case highlights the intricate surgical and radiotherapeutic decisions involved in managing recurrent grade I meningiomas, reinforcing the importance of multidisciplinary evaluation and individualized treatment strategies.

Indexed as

central nervous systemcraniotomymeningiomaparafalcine meningiomaradiation oncologyradiosurgery

Identifiers

PMID40918813
PMCPMC12412267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.